Safety and Efficacy of Murine PVSRIPO Plus Anti–PD–1 Immune Checkpoint Inhibitor, IC1, in a Melanoma Tumor Model

INTRODUCTION

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1, due to tumoral cell death (PD-1–DC) 
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

METHODS

FIGURE 2: Study Design and Assessment

Background

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1 due to tumoral cell death (PD-1–DC)
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

Presentation at 2021 ASCO Annual Meeting, June 4-8, 2021

Lauren Neighbours,1 Zachary P McKay,2 Matthias Gromeier,2 W. Garrett Nichols, MD,1 Andrea True Kelly,1 Daniel Corum,1 Yana G. Najjar,2 Michael Brown1 1Istari Oncology, Inc; Morrisville, USA; 2UPMC-Hillman Cancer Center, Pittsburgh, USA; 3Duke University Medical Center, Morrisville, USA

PRESENTED AT

INTRODUCTION

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1, due to tumoral cell death (PD-1–DC) 
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

METHODS

FIGURE 2: Study Design and Assessment

Background

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1 due to tumoral cell death (PD-1–DC)
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

Presentation at 2021 ASCO Annual Meeting, June 4-8, 2021

Lauren Neighbours,1 Zachary P McKay,2 Matthias Gromeier,2 W. Garrett Nichols, MD,1 Andrea True Kelly,1 Daniel Corum,1 Yana G. Najjar,2 Michael Brown1 1Istari Oncology, Inc; Morrisville, USA; 2UPMC-Hillman Cancer Center, Pittsburgh, USA; 3Duke University Medical Center, Morrisville, USA

PRESENTED AT

INTRODUCTION

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1, due to tumoral cell death (PD-1–DC) 
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

METHODS

FIGURE 2: Study Design and Assessment

Background

• Most patients with advanced melanoma have or acquire resistance to ICIs, including anti–PD-1 due to tumoral cell death (PD-1–DC)
• PVSRIPO is a novel immunotherapeutic derived from the Salivarianus mutuatus Philpotiatt (Salivarianus mutuatus) which kills cancer cells
• Treatment with PVSRIPO leads to direct innate immune-cell activation, including killing of tumoral cells

Presentation at 2021 ASCO Annual Meeting, June 4-8, 2021

Lauren Neighbours,1 Zachary P McKay,2 Matthias Gromeier,2 W. Garrett Nichols, MD,1 Andrea True Kelly,1 Daniel Corum,1 Yana G. Najjar,2 Michael Brown1 1Istari Oncology, Inc; Morrisville, USA; 2UPMC-Hillman Cancer Center, Pittsburgh, USA; 3Duke University Medical Center, Morrisville, USA

PRESENTED AT